SCHEMBL5873613

SCHEMBL5873613

CCCCCCCCCCCCCCCCCCC(N)CCCCCCCCC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 1/20 0.62
PLA2G2A P14555 1/20 0.62
S1PR2 O95136 5/20 0.61
S1PR1 P21453 5/20 0.61
S1PR3 Q99500 5/20 0.61
S1PR4 O95977 4/20 0.61
OPRM1 P35372 1/20 0.60
SPHK1 Q9NYA1 2/20 0.54
ALDH1A1 P00352 1/20 0.52
CYP2D6 P10635 2/20 0.50
LMNA P02545 2/20 0.50
GMNN O75496 1/20 0.50
POLB P06746 1/20 0.50
THPO P40225 1/20 0.50
MTOR P42345 1/20 0.50
BLM P54132 1/20 0.50
KDM4E B2RXH2 1/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10447807 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL10448552 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL4952280 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL1507463 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL20746344 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL20746505 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL23141152 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL8980625 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL20746346 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3
SCHEMBL20746426 1.00 PLA2G1B (0.62) PLA2G1BPLA2G2AS1PR2S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067687-B2 Ultrastable organofunctional microporous to mesoporous silica compositions BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2006-06-27 US disclosed
US-20040171482-A1 Ultrastable organofunctional microporous to mesoporous silica compositions BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2004-09-02 US disclosed
US-6713643-B2 USEFUL AS MOLECULAR SIEVES, SUPPORTS FOR CATALYSTS AND OTHER APPLICATIONS REQUIRING AN ORGANO GROUP ON SURFACES OF A SILICA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2004-03-30 US disclosed
US-20030054948-A1 Ultrastable organofunctional microporous to mesoporous silica compositions BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2003-03-20 US disclosed
WO-2002100526-A2 ULTRASTABLE ORGANOFUNCTIONAL MICROPOROUS TO MESOPOROUS SILICA COMPOSITIONS MICHIGAN STATE UNIVERSITY (US) 2002-12-19 WO disclosed
EP-0167969-B1 TRIS-ORGANOPHOSPHITE COMPOSITIONS HAVING IMPROVED HYDROLYTIC STABILITY Argus Chemical Corporation (US) 1989-09-13 EP disclosed
US-4707509-A Tris-organophosphite compositions having improved hydrolytic stability ARGUS CHEMICAL CORPORATION (US) 1987-11-17 US disclosed
EP-0143464-B1 PENTAERYTHRITOL-SPIRO-BIS-PHOSPHITE COMPOSITIONS HAVING IMPROVED HYDROLYTIC STABILITY Argus Chemical Corporation (US) 1987-07-08 EP disclosed
US-4650894-A STABILIZERS FOR VINYL CHLORIDE POLYMERS ARGUS CHEMICAL CORPORATION (US) 1987-03-17 US disclosed
EP-0167969-A2 Tris-organophosphite compositions having improved hydrolytic stability Argus Chemical Corporation (US) 1986-01-15 EP disclosed
EP-0143464-A2 Pentaerythritol-spiro-bis-phosphite compositions having improved hydrolytic stability Argus Chemical Corporation (US) 1985-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030054948-A1 Ultrastable organofunctional microporous to mesoporous silica compositions LPO, SPIN3, RPS3 PLA2G1B 4174/4885PLA2G2A 3880/4885S1PR2 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.